Companies › Alzamend Neuro
2 active drug programs in 10 registered trials: 4 Phase 1, 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Oncology, Other, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lithium Carbonate (AL001) Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor | IMPA1, GSK3A, GSK3B | Phase 1 | Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar … | Dec 2026 |
| ALZN002 Autologous dendritic cells pulsed with amyloid-beta E22W mutant peptide | – | Phase 1 | Alzheimer Disease | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06861842 | Lithium Carbonate (AL001) | Phase 4 | Healthy | Other | Apr 2025 |
| NCT07540338 | Lithium Carbonate (AL001) | Phase 1 | Bipolar I Disorder | Psychiatry | Dec 2026 |
| NCT06789783 | Lithium Carbonate (AL001) | Phase 2 | Cornelia De Lange Syndrome | Other | Dec 2026 |
| NCT06339034 | Lithium Carbonate (AL001) | Phase 1 | Parkinson Disease | Neurology | Aug 2027 |
| NCT06776848 | Lithium Carbonate (AL001) | Phase 1 | Proven Pathogenic or Probably Pathogenic TBR1 Variant | Other | Sep 2027 |
| NCT06184581 | Lithium Carbonate (AL001) | Phase 4 | Bipolar II Disorder | Psychiatry | Dec 2027 |
| NCT05834296 | ALZN002 | Phase 1 | Alzheimer Disease | Neurology | Mar 2028 |
| NCT05973786 | Lithium Carbonate (AL001) | Phase 3 | Bipolar Depression | Psychiatry | Jun 2028 |
| NCT05913947 | Lithium Carbonate (AL001) | Phase 4 | Depression, Bipolar | Psychiatry | Sep 2028 |
| NCT06051240 | Lithium Carbonate (AL001) | Phase 2 | Cognitive Impairment | Oncology | Aug 2030 |
Cash of $8m on 2026-07-31; operating cash outflow about $5m a year; runway about 20 months at that burn, to Mar 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.